Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
QJM ; 115(10): 665-672, 2022 Oct 25.
Article in English | MEDLINE | ID: covidwho-1684796

ABSTRACT

BACKGROUND: The evidence regarding the efficacy of vitamin D supplementation in reducing severity of COVID-19 is still insufficient. This is partially due to the lack of primary robust trial-based data and heterogeneous study designs. AIM: This evidence summary, aims to study the effect of vitamin D supplementation on morbidity and mortality in hospitalized COVID-19 patients.Design: Evidence summary of systematic reviews. METHODS: For this study, systematic reviews and meta-analysis published from December 2019 to January 2022 presenting the impact of vitamin D supplementation on COVID-19 severity were screened and selected from PubMed and Google scholar. After initial screening, 10 eligible reviews were identified and quality of included reviews were assessed using AMSTAR and GRADE tools and overlapping among the primary studies used were also assessed. RESULTS: The number of primary studies included in the systematic reviews ranged from 3 to 13. Meta-analysis of seven systematic reviews showed strong evidence that vitamin D supplementation reduces the risk of mortality (Odds ratio: 0.48, 95% CI: 0.346-0.664; P < 0.001) in COVID patients. It was also observed that supplementation reduces the need for intensive care (Odds ratio: 0.35; 95%CI: 0.28-0.44; P < 0.001) and mechanical ventilation (Odds ratio: 0.54; 95% CI: 0.411-0.708; P < 0.001) requirement. The findings were robust and reliable as level of heterogeneity was considerably low. However the included studies were of varied quality. Qualitative analysis showed that supplements (oral and IV) are well tolerated, safe and effective in COVID patients. CONCLUSION: The findings of this study show that vitamin D supplementation is effective in reducing the COVID-19 severity. Hence, vitamin D should be recommended as an adjuvant therapy for COVID-19.However, more robust and larger trials are required to substantiate it further.


Subject(s)
COVID-19 , Dietary Supplements , Vitamin D , Humans , COVID-19/prevention & control , Meta-Analysis as Topic , Systematic Reviews as Topic , Vitamin D/therapeutic use , Clinical Trials as Topic
2.
Asia Pacific Journal of Health Management ; 16(3), 2021.
Article in English | Scopus | ID: covidwho-1471273

ABSTRACT

BACKGROUND: The Coronavirus disease 2019 (COVID-19) has emerged as a public health crisis globally. Management of old age homes have been challenged during the ongoing pandemic crisis, as the elderlies are by far the most vulnerable population group in context to prone to infection of COVID-19 disease. OBJECTIVE: The study intended to understand the effect of COVID-19 on western Indian elderly care homes, the actions taken by the administration, and the challenges faced during and post-lockdown period. METHOD: A total of 44 care homes across three states of western India were contacted for data collection during the period of September-December 2020. Semi-structured interviews of the administrators were taken to gather the required information to achieve the study objectives. RESULTS: Out of 44 care homes, ten care homes reported 169 cases of coronavirus infection and seven deaths. Hence, the rate of reported COVID-19 cases was found to be 1074 per 10,000 residents. DISCUSSION: Results of the study indicated the significant steps taken by these old-age care homes to stave off the infection spread among the occupants. It was observed that an average of 26% of the occupants was sent back to their home/relative's home before the lockdown to decongest the care homes. Care homes in western India seemed to have a very low infection rate and a very low number of deaths as compared to the Global Scenario. The present study also highlights the gaps in policy and calls for urgent action by the government for the regulation of old age homes in India. © 2021 Montenegrin Sports Academy. All rights reserved.

3.
QJM ; 114(7): 476-495, 2021 Nov 05.
Article in English | MEDLINE | ID: covidwho-1320324

ABSTRACT

BACKGROUND: Given the limited and diverse nature of published literature related to COVID-19 in pediatrics, it is imperative to provide evidence-based summary of disease characteristics for guiding policy decisions. We aim to provide comprehensive overview of epidemiological, clinical and biomarker profile of COVID-19 infection in pediatric population. METHODS: For this umbrella review, published systematic reviews from PubMed and pre-print databases were screened. Literature search was conducted from December 2019 to April 2021. Details of clinical, radiological and laboratory features were collected from each review. Qualitative observations were synthesized and pooled prevalence of mortality and asymptomatic cases were assessed using meta-analysis. RESULTS: Evidence synthesis of 38 systematic reviews included total 1145 studies and 334 398 children and adolescents. Review revealed that COVID-19 is relatively milder with better prognosis in pediatrics. However, patients with comorbidity are at higher risk. Meta-analysis of reviews showed that 21.17% (95% CI: 17.818-24.729) of the patients were asymptomatic and mortality rate was 0.12% (95% CI: 0.0356-0.246). Though there was no publication bias, significant heterogeneity was observed. Fever (48-64%) and cough (35-55.9%) were common symptoms, affecting almost every alternate patient. Ground-glass opacities (prevalence range: 27.4-61.5%) was most frequent radiographic observation. Rise in C-reactive protein, lactate dehydrogenase and D-dimer ranged from 14% to 54%, 12.2-50% and 0.3-67%, respectively. Some of the included reviews (44.7%-AMSTAR; 13.2%-GRADE) were of lower quality. CONCLUSION: Current umbrella review provides most updated information regarding characteristics of COVID-19 infection in pediatrics and can be used to guide policy decision regarding vaccination prioritization, early screening and identification of at-risk population.


Subject(s)
COVID-19 , Pediatrics , Adolescent , Biomarkers , Child , Cough , Humans , SARS-CoV-2
4.
QJM ; 113(12): 841-850, 2020 Dec 01.
Article in English | MEDLINE | ID: covidwho-1066397

ABSTRACT

Coronavirus disease 2019 (COVID-19) is a novel virus with continuously evolving transmission trends. Contact tracing and quarantining of positive cases are chief strategies of disease control that has been accepted globally, though scientific knowledge regarding household transmission of the COVID-19 through contact of positive case is sparse. Current systematic review was planned to assess global statistics and characteristics of household secondary attack rate (SAR) of COVID-19. Eligible articles were retrieved through search of-MEDLINE, SCOPUS and EMBASE for the period December 2019 to 15 June 2020. Search terms were developed to identify articles reporting household SARs in various countries. After initial screening of 326 articles, 13 eligible studies were included in the final evidence synthesis. We found that SAR varies widely across countries with lowest reported rate as 4.6% and highest as 49.56%. The rates were unaffected by confounders such as population of the country, lockdown status and geographic location. Review suggested greater vulnerability of spouse and elderly population for secondary transmission than other household members. It was also observed that quarantining and isolation are most effective strategies for prevention of the secondary transmission of the disease. Symptomatic status of the index case emerged to be a critical factor, with very low transmission probability during asymptomatic phase. Present review findings recommend that adequate measures should be provided to protect the vulnerable population as only case tracing and quarantining might be insufficient. It should be combined with advisory for limiting household contacts and active surveillance for symptom onset.


Subject(s)
COVID-19/transmission , Community-Acquired Infections/transmission , Family Characteristics , Family Health , Pneumonia, Viral/transmission , Community-Acquired Infections/virology , Humans , Pneumonia, Viral/virology , Risk Factors , SARS-CoV-2
5.
QJM ; 114(3): 175-181, 2021 May 19.
Article in English | MEDLINE | ID: covidwho-1044091

ABSTRACT

OBJECTIVE: Current meta-analysis aims to understand the effect of oral supplementation of vitamin D on intensive care unit (ICU) requirement and mortality in hospitalized COVID-19 patients. METHODS: Databases PubMed, preprint servers, and google scholar were searched from December 2019 to December 2020. Authors searched for the articles assessing role of vitamin D supplementation on COVID-19. Cochrane RevMan tool was used for quantitative assessment of the data, where heterogeneity was assessed using I2 and Q statistics and data was expressed using odds ratio with 95% confidence interval. RESULTS: Final meta-analysis involved pooled data of 532 hospitalized patients (189 on vitamin D supplementation and 343 on usual care/placebo) of COVID-19 from three studies (Two randomized controlled trials, one retrospective case-control study). Statistically (p<0.0001) lower ICU requirement was observed in patients with vitamin D supplementation as compared to patients without supplementations (odds ratio: 0.36; 95% CI: 0.210-0.626). However, it suffered from significant heterogeneity, which reduced after sensitivity analysis. In case of mortality, vitamin D supplements has comparable findings with placebo treatment/usual care (odds ratio: 0.93; 95% CI: 0.413-2.113; p=0.87). The studies did not show any publication bias and had fair quality score. Subgroup analysis could not be performed due to limited number of studies and hence dose and duration dependent effect of vitamin D could not be evaluated. CONCLUSIONS: Although the current meta-analysis findings indicate potential role of vitamin D in improving COVID-19 severity in hospitalized patients, more robust data from randomized controlled trials are needed to substantiate its effects on mortality.


Subject(s)
COVID-19 Drug Treatment , COVID-19/mortality , Critical Care , Pneumonia, Viral/drug therapy , Pneumonia, Viral/mortality , Vitamin D/administration & dosage , Administration, Oral , Hospitalization , Humans , Pneumonia, Viral/virology , SARS-CoV-2 , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL